{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT04140500",
            "orgStudyIdInfo": {
                "id": "NP41300"
            },
            "secondaryIdInfos": [
                {
                    "id": "2019-000779-18",
                    "type": "EUDRACT_NUMBER"
                }
            ],
            "organization": {
                "fullName": "Hoffmann-La Roche",
                "class": "INDUSTRY"
            },
            "briefTitle": "Dose Escalation Study of a PD1-LAG3 Bispecific Antibody in Patients With Advanced and/or Metastatic Solid Tumors",
            "officialTitle": "An Open Label, Multicenter, Dose Escalation, Phase 1 Study to Evaluate Safety/Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Anti Tumor Activity of RO7247669, a PD1-LAG3 Bispecific Antibody, in Patients With Advanced and/or Metastatic Solid Tumors",
            "therapeuticArea": [
                "Oncology and Hematology"
            ],
            "study": "dose-escalation-study-of-a-bispecific-antibody-in-patients-with-advanced-and-or-metastatic-solid-tumors"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-07",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2019-11-11",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2025-12-31",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2025-12-31",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2019-10-24",
            "studyFirstSubmitQcDate": "2019-10-24",
            "studyFirstPostDateStruct": {
                "date": "2019-10-28",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-07-10",
            "lastUpdatePostDateStruct": {
                "date": "2024-07-11",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Hoffmann-La Roche",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "This is a first-in-human, open-label, multicenter, Phase I multiple-ascending dose (MAD) study of RO7247669, an anti PD-1 (programmed death-1) and LAG-3 (Lymphocyte-activation gene 3) bispecific antibody, for participants with advanced and/or metastatic solid tumors. This study aims to establish the maximum tolerated dose (MTD) and/or define the recommended phase 2 dose (RP2D) based on the safety, tolerability, pharmacokinetic (PK) and/or pharmacodynamic (PD) profile of RO7247669, and to evaluate preliminary anti-tumor activity in participants with solid tumors. An expansion part of the study is planned to enroll tumor-specific cohorts to evaluate anti-tumor activity of the MTD and/or RP2D of RO7247669 and to confirm safety and tolerability in participants with selected tumor types."
        },
        "conditionsModule": {
            "conditions": [
                "Solid Tumors",
                "Metastatic Melanoma",
                "Non-small Cell Lung Cancer",
                "Esophageal Squamous Cell Carcinoma"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1",
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "NON_RANDOMIZED",
                "interventionModel": "SINGLE_GROUP",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 320,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Part A: Single-Agent Dose Escalation",
                    "type": "EXPERIMENTAL",
                    "description": "Participants will receive RO7247669 every 2 weeks (Q2W) or every 3 weeks (Q3W) up to the maximum tolerated dose (MTD) until disease progression, unacceptable drug toxicity, or withdrawal of consent, for up to 24 months.",
                    "interventionNames": [
                        "Drug: RO7247669"
                    ]
                },
                {
                    "label": "Part B: Tumor Specific Expansion Cohorts",
                    "type": "EXPERIMENTAL",
                    "description": "Participants with selected solid tumor indications will receive RO7247669 at a dose derived from Part A until disease progression, unacceptable drug toxicity, or withdrawal of consent, for up to 24 months.",
                    "interventionNames": [
                        "Drug: RO7247669"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "RO7247669",
                    "description": "Participants will receive intravenous (IV) RO7247669 at different doses either every 2 weeks (Q2W) or every 3 weeks (Q3W)",
                    "armGroupLabels": [
                        "Part A: Single-Agent Dose Escalation",
                        "Part B: Tumor Specific Expansion Cohorts"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Part A: Percentage of Participants with Dose-Limiting Toxicities (DLTs)",
                    "timeFrame": "Days 1-21 (Q2W dosing) or Days 1-28 (Q3W dosing) of Cycle 1"
                },
                {
                    "measure": "Part A: Percentage of Participants with Adverse Events",
                    "timeFrame": "Baseline through the end of study (up to 24 months)"
                },
                {
                    "measure": "Part B: Objective Response Rate (ORR)",
                    "timeFrame": "Up to 24 months"
                },
                {
                    "measure": "Part B: Disease Control Rate (DCR), Defined as ORR + Stable Disease Rate (SDR)",
                    "timeFrame": "Up to 24 months"
                },
                {
                    "measure": "Part B: Duration of Response (DOR)",
                    "timeFrame": "Up to 24 months"
                },
                {
                    "measure": "Part B: Progression-free Survival (PFS), Defined as the Time from the First Study Treatment to the First Occurrence of Progression per Investigator Assessment or Death from any Cause, Whichever Occurs First",
                    "timeFrame": "Up to 24 months"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Parts A and B: Maximum Concentration (Cmax) of RO7247669",
                    "timeFrame": "At pre-defined intervals from Day 1 of Cycle 1 through final study visit (up to 24 months)"
                },
                {
                    "measure": "Parts A and B: Time of Maximum Concentration (Tmax) of RO7247669",
                    "timeFrame": "At pre-defined intervals from Day 1 of Cycle 1 through final study visit (up to 24 months)"
                },
                {
                    "measure": "Parts A and B: Clearance (CL) of RO7247669",
                    "timeFrame": "At pre-defined intervals from Day 1 of Cycle 1 through final study visit (up to 24 months)"
                },
                {
                    "measure": "Parts A and B: Volume of Distribution at Steady State (Vss) of RO7247669",
                    "timeFrame": "At pre-defined intervals from Day 1 of Cycle 1 through final study visit (up to 24 months)"
                },
                {
                    "measure": "Parts A and B: Area Under the Curve (AUC) of RO7247669",
                    "timeFrame": "At pre-defined intervals from Day 1 of Cycle 1 through final study visit (up to 24 months)"
                },
                {
                    "measure": "Parts A and B: Half-Life (T1/2) of RO7247669",
                    "timeFrame": "At pre-defined intervals from Day 1 of Cycle 1 through final study visit (up to 24 months)"
                },
                {
                    "measure": "Parts A and B: Percentage of Participants with Anti-Drug Antibodies (ADA) to RO7247669",
                    "timeFrame": "Day 1 of each Cycle, starting with Cycle 1, through final study visit (up to 24 months)"
                },
                {
                    "measure": "Part B: Change from Baseline in T-Cell Activity",
                    "timeFrame": "At pre-defined intervals from Day 1 of Cycle 1 through final study visit (up to 24 months)"
                },
                {
                    "measure": "Part A: Percentage of Receptors Occupied by RO7247669",
                    "timeFrame": "At pre-defined intervals from Day 1 of Cycle 1 through final study visit (up to 24 months)"
                },
                {
                    "measure": "Part A: ORR",
                    "timeFrame": "At pre-defined intervals from initial dose up to 24 months"
                },
                {
                    "measure": "Part A: DCR",
                    "timeFrame": "At pre-defined intervals from initial dose up to 24 months"
                },
                {
                    "measure": "Part A: PFS",
                    "timeFrame": "At pre-defined intervals from initial dose up to 24 months"
                },
                {
                    "measure": "Part A: DOR",
                    "timeFrame": "At pre-defined intervals from initial dose up to 24 months"
                },
                {
                    "measure": "Part B: Percentage of Participants with Adverse Events",
                    "timeFrame": "Baseline through the end of study (up to 24 months)"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion criteria\n\n* Patient must have histologically or cytologically confirmed advanced and/or metastatic solid tumor malignancies for which standard curative or palliative measures do not exist, are no longer effective, or are not acceptable to the patient\n* Eastern Cooperative Oncology Group Performance Status 0-1\n* Fresh biopsies may be required\n* Women of childbearing potential and male participants must agree to remain abstinent or use contraceptive methods as defined by the protocol\n\nAdditional Specific Inclusion Criteria for Participants with Melanoma\n\n* Histologically confirmed, unresectable stage III or stage IV melanoma\n* Not more than 2 prior lines of treatment for metastatic disease are allowed prior to enrolling in the study\n* Prior treatment with an approved anti-PD-1 or anti-PD-L1 agent\n\nAdditional Specific Inclusion Criteria for Participants with Non-Small Cell Lung Cancer who Previously Received Treatment for Metastatic Disease\n\n* Participants with histologically confirmed advanced non-small cell lung cancer\n* Not more than 2 prior lines of treatment for metastatic disease are allowed prior to enrolling in the study\n* Previously treated with approved PD-L1/PD-1 inhibitors\n* Tumor PD-L1 expression as determined by immunohistochemistry assay of archival tumor tissue or tissue obtained at screening\n\nAdditional Specific Inclusion Criteria for Participants with Esophageal Squamous Cell Carcinoma\n\n* Participants whose major lesion was histologically confirmed as squamous cell carcinoma or adenosquamous cell carcinoma of the esophagus\n* Participants who have previously received not more than 1 prior line of treatment for metastatic disease prior to enrolling in the study\n\nAdditional Specific Inclusion Criteria for Participants with Non-Small Cell Lung Cancer who Previously did not Receive Treatment for Metastatic Disease\n\n* Participants with histologically confirmed advanced non-small cell lung cancer\n* Tumor PD-L1 expression as determined by immunohistochemistry assay of archival tumor tissue or tissue obtained at screening\n\nExclusion criteria\n\n* Pregnancy, lactation, or breastfeeding\n* Known hypersensitivity to any of the components of RO7247669\n* Active or untreated central nervous system (CNS) metastases\n* An active second malignancy\n* Evidence of concomitant diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that may affect the interpretation of the results or render the participant at high risk from treatment complications\n* Positive HIV, hepatitis B, or hepatitis C test result\n* Known active or uncontrolled bacterial, viral, fungal, mycobacterial, parasitic, or other infection\n* Vaccination with live vaccines within 28 days prior to Cycle 1 Day 1\n* Treatment with oral or IV antibiotics within 2 weeks prior to Cycle 1 Day 1\n* Active or history of autoimmune disease or immune deficiency\n* Prior treatment with adoptive cell therapies, such as CAR-T therapies\n* Concurrent therapy with any other investigational drug \\< 28 days or 5 half-lives of the drug, whichever is shorter, prior to the first RO7247669 administration\n* Regular immunosuppressive therapy\n* Radiotherapy within the last 4 weeks before start of study drug treatment, with the exception of limited palliative radiotherapy\n* Prior treatment with a lymphocyte activation gene-3 (LAG-3) inhibitor\n\nAdditional Specific Exclusion Criteria for Participants with Non-Small Cell Lung Cancer who Previously Received Treatment for Metastatic Disease\n\n* Participants with the following muations, rearrangements, translocations are not eligible: EGFR, ALK, ROS1, BRAFV600E, and NTRK\n\nAdditional Specific Exclusion Criteria for Participants with Esophageal Squamous Cell Carcinoma\n\n* Prior therapy with any immunomodulatory agents\n\nAdditional Specific Exclusion Criteria for Participants with Non-Small Cell Lung Cancer who Previously did not Receive Treatment for Metastatic Disease\n\n* Prior therapy for metastatic disease is not permitted\n* Neo-adjuvant anti-PD-1 or anti-PD-L1 therapy is not allowed",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Reference Study ID: NP41300 https://forpatients.roche.com/",
                    "role": "CONTACT",
                    "phone": "888-662-6728 (U.S. and Canada)",
                    "email": "global-roche-genentech-trials@gene.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Clinical Trials",
                    "affiliation": "Hoffmann-La Roche",
                    "role": "STUDY_DIRECTOR"
                }
            ],
            "locations": [
                {
                    "facility": "Sharp Memorial Hospital",
                    "status": "WITHDRAWN",
                    "city": "San Diego",
                    "state": "California",
                    "zip": "92123",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 32.71533,
                        "lon": -117.15726
                    }
                },
                {
                    "facility": "Henry Ford Hospital; Hematology/Oncology Phase 1",
                    "status": "WITHDRAWN",
                    "city": "Detroit",
                    "state": "Michigan",
                    "zip": "48202",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 42.33143,
                        "lon": -83.04575
                    }
                },
                {
                    "facility": "Hospital de Clinicas de Porto Alegre X; Centro de Pesquisa Clinica",
                    "status": "WITHDRAWN",
                    "city": "Porto Alegre",
                    "state": "RS",
                    "zip": "90035-903",
                    "country": "Brazil",
                    "geoPoint": {
                        "lat": -30.03306,
                        "lon": -51.23
                    }
                },
                {
                    "facility": "Instituto do Cancer do Estado de Sao Paulo - ICESP",
                    "status": "WITHDRAWN",
                    "city": "Sao Paulo",
                    "state": "SP",
                    "zip": "01246-000",
                    "country": "Brazil",
                    "geoPoint": {
                        "lat": -23.5475,
                        "lon": -46.63611
                    }
                },
                {
                    "facility": "Rigshospitalet; Fase 1 Enhed - Onkologi",
                    "status": "RECRUITING",
                    "city": "K\u00f8benhavn \u00d8",
                    "zip": "2100",
                    "country": "Denmark",
                    "geoPoint": {
                        "lat": 55.67594,
                        "lon": 12.56553
                    }
                },
                {
                    "facility": "Odense Universitetshospital, Onkologisk Afdeling R",
                    "status": "ACTIVE_NOT_RECRUITING",
                    "city": "Odense C",
                    "zip": "5000",
                    "country": "Denmark",
                    "geoPoint": {
                        "lat": 55.39594,
                        "lon": 10.38831
                    }
                },
                {
                    "facility": "LLC Arensia Explorer Medicine",
                    "status": "RECRUITING",
                    "city": "Tbilisi",
                    "zip": "0112",
                    "country": "Georgia",
                    "geoPoint": {
                        "lat": 41.69411,
                        "lon": 44.83368
                    }
                },
                {
                    "facility": "Hadassah University Hospital - Ein Kerem; Oncology",
                    "status": "ACTIVE_NOT_RECRUITING",
                    "city": "Jerusalem",
                    "zip": "9112001",
                    "country": "Israel",
                    "geoPoint": {
                        "lat": 31.76904,
                        "lon": 35.21633
                    }
                },
                {
                    "facility": "Rabin MC; Davidof Center - Oncology Institute",
                    "status": "RECRUITING",
                    "city": "Petach Tikva",
                    "zip": "4941492",
                    "country": "Israel",
                    "geoPoint": {
                        "lat": 32.08707,
                        "lon": 34.88747
                    }
                },
                {
                    "facility": "Chaim Sheba medical center, Oncology division",
                    "status": "COMPLETED",
                    "city": "Ramat Gan",
                    "zip": "5262000",
                    "country": "Israel",
                    "geoPoint": {
                        "lat": 32.08227,
                        "lon": 34.81065
                    }
                },
                {
                    "facility": "Seoul National University Bundang Hospital",
                    "status": "COMPLETED",
                    "city": "Seongnam-si",
                    "zip": "463-707",
                    "country": "Korea, Republic of",
                    "geoPoint": {
                        "lat": 37.43861,
                        "lon": 127.13778
                    }
                },
                {
                    "facility": "Seoul National University Hospital",
                    "status": "COMPLETED",
                    "city": "Seoul",
                    "zip": "03080",
                    "country": "Korea, Republic of",
                    "geoPoint": {
                        "lat": 37.566,
                        "lon": 126.9784
                    }
                },
                {
                    "facility": "Severance Hospital, Yonsei University Health System",
                    "status": "TERMINATED",
                    "city": "Seoul",
                    "zip": "03722",
                    "country": "Korea, Republic of",
                    "geoPoint": {
                        "lat": 37.566,
                        "lon": 126.9784
                    }
                },
                {
                    "facility": "Asan Medical Center",
                    "status": "COMPLETED",
                    "city": "Seoul",
                    "zip": "05505",
                    "country": "Korea, Republic of",
                    "geoPoint": {
                        "lat": 37.566,
                        "lon": 126.9784
                    }
                },
                {
                    "facility": "Hospital Civil de Guadalajara Fray Antonio Alcalde",
                    "status": "RECRUITING",
                    "city": "Guadalajara",
                    "state": "Jalisco",
                    "zip": "44280",
                    "country": "Mexico",
                    "geoPoint": {
                        "lat": 20.66682,
                        "lon": -103.39182
                    }
                },
                {
                    "facility": "Inst. Nacional de Cancerolog\u00eda; Pneumology",
                    "status": "RECRUITING",
                    "city": "Mexico City",
                    "state": "Mexico CITY (federal District)",
                    "zip": "14080",
                    "country": "Mexico",
                    "geoPoint": {
                        "lat": 19.42847,
                        "lon": -99.12766
                    }
                },
                {
                    "facility": "Consultorio M\u00e9dico Jordi Guzm\u00e1n Casta",
                    "status": "RECRUITING",
                    "city": "Quer\u00e9taro",
                    "state": "Queretaro",
                    "zip": "76226",
                    "country": "Mexico"
                },
                {
                    "facility": "The Institute of Oncology, ARENSIA Exploratory Medicine",
                    "status": "RECRUITING",
                    "city": "Chisinau",
                    "zip": "MD-2025",
                    "country": "Moldova, Republic of",
                    "geoPoint": {
                        "lat": 47.00556,
                        "lon": 28.8575
                    }
                },
                {
                    "facility": "IPO do Porto; Servico de Oncologia Medica",
                    "status": "WITHDRAWN",
                    "city": "Porto",
                    "zip": "4200-072",
                    "country": "Portugal",
                    "geoPoint": {
                        "lat": 41.14961,
                        "lon": -8.61099
                    }
                },
                {
                    "facility": "National University Hospital; National University Cancer Institute, Singapore (NCIS)",
                    "status": "RECRUITING",
                    "city": "Singapore",
                    "zip": "119228",
                    "country": "Singapore",
                    "geoPoint": {
                        "lat": 1.28967,
                        "lon": 103.85007
                    }
                },
                {
                    "facility": "National Cancer Centre; Medical Oncology",
                    "status": "RECRUITING",
                    "city": "Singapore",
                    "zip": "168583",
                    "country": "Singapore",
                    "geoPoint": {
                        "lat": 1.28967,
                        "lon": 103.85007
                    }
                },
                {
                    "facility": "Clinica Universitaria de Navarra; Servicio de Oncologia",
                    "status": "RECRUITING",
                    "city": "Pamplona",
                    "state": "Navarra",
                    "zip": "31008",
                    "country": "Spain",
                    "geoPoint": {
                        "lat": 42.81687,
                        "lon": -1.64323
                    }
                },
                {
                    "facility": "Hospital del Mar; Servicio de Oncologia",
                    "status": "RECRUITING",
                    "city": "Barcelona",
                    "zip": "08003",
                    "country": "Spain",
                    "geoPoint": {
                        "lat": 41.38879,
                        "lon": 2.15899
                    }
                },
                {
                    "facility": "Vall d?Hebron Institute of Oncology (VHIO), Barcelona",
                    "status": "RECRUITING",
                    "city": "Barcelona",
                    "zip": "08035",
                    "country": "Spain",
                    "geoPoint": {
                        "lat": 41.38879,
                        "lon": 2.15899
                    }
                },
                {
                    "facility": "Clinica Universidad de Navarra Madrid; Servicio de Oncolog\u00eda",
                    "status": "RECRUITING",
                    "city": "Madrid",
                    "zip": "28027",
                    "country": "Spain",
                    "geoPoint": {
                        "lat": 40.4165,
                        "lon": -3.70256
                    }
                },
                {
                    "facility": "START Madrid-FJD, Hospital Fundacion Jimenez Diaz",
                    "status": "RECRUITING",
                    "city": "Madrid",
                    "zip": "28040",
                    "country": "Spain",
                    "geoPoint": {
                        "lat": 40.4165,
                        "lon": -3.70256
                    }
                },
                {
                    "facility": "START Madrid. Centro Integral Oncologico Clara Campal; CIOCC",
                    "status": "RECRUITING",
                    "city": "Madrid",
                    "zip": "28050",
                    "country": "Spain",
                    "geoPoint": {
                        "lat": 40.4165,
                        "lon": -3.70256
                    }
                },
                {
                    "facility": "Adana City Hospital, Medical Oncology",
                    "status": "ACTIVE_NOT_RECRUITING",
                    "city": "Adana",
                    "zip": "01060",
                    "country": "Turkey",
                    "geoPoint": {
                        "lat": 37.00167,
                        "lon": 35.32889
                    }
                },
                {
                    "facility": "Ankara City Hospital; Oncology",
                    "status": "RECRUITING",
                    "city": "Ankara",
                    "zip": "06800",
                    "country": "Turkey",
                    "geoPoint": {
                        "lat": 39.91987,
                        "lon": 32.85427
                    }
                },
                {
                    "facility": "Koc University Hospital; Oncology",
                    "status": "RECRUITING",
                    "city": "Istanbul",
                    "country": "Turkey",
                    "geoPoint": {
                        "lat": 41.01384,
                        "lon": 28.94966
                    }
                },
                {
                    "facility": "Hacettepe Uni Medical Faculty Hospital; Oncology Dept",
                    "status": "RECRUITING",
                    "city": "Sihhiye/Ankara",
                    "zip": "06230",
                    "country": "Turkey"
                },
                {
                    "facility": "Ankara Abdurrahman Yurtaslan Oncology Training and Research Hospital Phase 1 Center",
                    "status": "RECRUITING",
                    "city": "Yen?mahalle",
                    "zip": "06200",
                    "country": "Turkey"
                },
                {
                    "facility": "Queen Elizabeth Hospital",
                    "status": "RECRUITING",
                    "city": "Birmingham",
                    "zip": "B15 2TH",
                    "country": "United Kingdom",
                    "geoPoint": {
                        "lat": 52.48142,
                        "lon": -1.89983
                    }
                },
                {
                    "facility": "Christie Hospital NHS Trust; Experimental Cancer Medicine Team",
                    "status": "COMPLETED",
                    "city": "Manchester",
                    "zip": "M20 4BX",
                    "country": "United Kingdom",
                    "geoPoint": {
                        "lat": 53.48095,
                        "lon": -2.23743
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "YES",
            "description": "Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/ourmember/roche/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm)."
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000077277",
                    "term": "Esophageal Squamous Cell Carcinoma"
                }
            ],
            "ancestors": [
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000009371",
                    "term": "Neoplasms by Site"
                },
                {
                    "id": "D000009370",
                    "term": "Neoplasms by Histologic Type"
                },
                {
                    "id": "D000002294",
                    "term": "Carcinoma, Squamous Cell"
                },
                {
                    "id": "D000002277",
                    "term": "Carcinoma"
                },
                {
                    "id": "D000009375",
                    "term": "Neoplasms, Glandular and Epithelial"
                },
                {
                    "id": "D000018307",
                    "term": "Neoplasms, Squamous Cell"
                },
                {
                    "id": "D000004938",
                    "term": "Esophageal Neoplasms"
                },
                {
                    "id": "D000005770",
                    "term": "Gastrointestinal Neoplasms"
                },
                {
                    "id": "D000004067",
                    "term": "Digestive System Neoplasms"
                },
                {
                    "id": "D000006258",
                    "term": "Head and Neck Neoplasms"
                },
                {
                    "id": "D000004066",
                    "term": "Digestive System Diseases"
                },
                {
                    "id": "D000004935",
                    "term": "Esophageal Diseases"
                },
                {
                    "id": "D000005767",
                    "term": "Gastrointestinal Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M5546",
                    "name": "Carcinoma, Non-Small-Cell Lung",
                    "relevance": "LOW"
                },
                {
                    "id": "M5534",
                    "name": "Carcinoma",
                    "relevance": "LOW"
                },
                {
                    "id": "M11172",
                    "name": "Lung Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M5550",
                    "name": "Carcinoma, Squamous Cell",
                    "relevance": "LOW"
                },
                {
                    "id": "M11528",
                    "name": "Melanoma",
                    "relevance": "LOW"
                },
                {
                    "id": "M1733",
                    "name": "Esophageal Squamous Cell Carcinoma",
                    "asFound": "Esophageal Squamous Cell Carcinoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "M12315",
                    "name": "Neoplasms by Histologic Type",
                    "relevance": "LOW"
                },
                {
                    "id": "M12320",
                    "name": "Neoplasms, Glandular and Epithelial",
                    "relevance": "LOW"
                },
                {
                    "id": "M20451",
                    "name": "Neoplasms, Squamous Cell",
                    "relevance": "LOW"
                },
                {
                    "id": "M8088",
                    "name": "Esophageal Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M7256",
                    "name": "Digestive System Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M8886",
                    "name": "Gastrointestinal Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M9348",
                    "name": "Head and Neck Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M7255",
                    "name": "Digestive System Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M8883",
                    "name": "Gastrointestinal Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M8085",
                    "name": "Esophageal Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "T2141",
                    "name": "Esophageal Cancer",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "BC08",
                    "name": "Respiratory Tract (Lung and Bronchial) Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC17",
                    "name": "Skin and Connective Tissue Diseases"
                },
                {
                    "abbrev": "BC06",
                    "name": "Digestive System Diseases"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "browseLeaves": [
                {
                    "id": "M4225",
                    "name": "Antibodies",
                    "relevance": "LOW"
                },
                {
                    "id": "M20194",
                    "name": "Antibodies, Bispecific",
                    "relevance": "LOW"
                },
                {
                    "id": "M10184",
                    "name": "Immunoglobulins",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}